Eradication of Missing Liver Metastases After Fiducial Placement

Journal of Gastrointestinal Surgery

Volumn 20, Issue 6, 2016, Pages 1173-1178

  Passot, Guillaume ^a   Odisio, Bruno C ^a   Zorzi, Daria ^a   Mahvash, Armeen ^a   Gupta, Sanjay ^a   Wallace, Michael J ^a   Kim, Bradford J ^a   Yamashita, Suguru ^a   Conrad, Claudius ^a   Aloia, Thomas A ^a   Vauthey, Jean Nicolas ^a   Chun, Yun Shin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Disappearing liver metastases; Fiducial

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; DIAGNOSTIC IMAGING; EVALUATION STUDY; FIDUCIAL MARKER; FOLLOW UP; HUMAN; LIVER RESECTION; LIVER TUMOR; NEOADJUVANT THERAPY; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FIDUCIAL MARKERS; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84954474376     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-016-3079-1     Document Type: Article

References (17)

1. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncology 2013;14:1208-1215.
2. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. Journal of Clinical Oncology 2008;26:5344-5351.
3. Benoist S, Brouquet A, Penna C, Julie C, El Hajjam M, Chagnon S, Mitry E, Rougier P, Nordlinger B. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? Journal of Clinical Oncology 2006;24:3939-3945.
4. Auer RC, White RR, Kemeny NE, Schwartz LH, Shia J, Blumgart LH, Dematteo RP, Fong Y, Jarnagin WR, D’Angelica MI. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010;116:1502-1509.
5. Van Vledder MG, De Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? Journal of Gastrointestinal Surgery 2010;14:1691-1700.
6. Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB 2013;15:91-103.
7. Zalinski S, Abdalla EK, Mahvash A, Vauthey JN. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Annals of Surgical Oncology 2009;16:1208-1211.
8. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Annals of Surgical Oncology 2006;13:1261-1268.
9. Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Annals of Surgery 2015; Epub.
10. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. Journal of Clinical Oncology 2011;29:1083-1090.
11. Evrard S, Poston G, Kissmeyer-Nielsen P, Diallo A, Desolneux G, Brouste V, Lalet C, Mortensen F, Stattner S, Fenwick S, Malik H, Konstantinidis I, DeMatteo R, D’Angelica M, Allen P, Jarnagin W, Mathoulin-Pelissier S, Fong Y. Combined ablation and resection (CARe) as an effective parenchymal sparing treatment for extensive colorectal liver metastases. PloS One 2014;9:e114404.
12. Sturesson C, Nilsson J, Lindell G, Andersson RG, Keussen I. Disappearing liver metastases from colorectal cancer: impact of modern imaging modalities. HPB 2015;17:983-987.
13. Aoki T, Murakami M, Koizumi T, Kusano T, Fujimori A, Enami Y, Matsuda K, Goto S, Watanabe M, Otsuka K. Preoperative tattooing for precise and expedient localization of landmark in laparoscopic liver resection. Journal of the American College of Surgeons 2015;221:e97-e101.
14. Ntourakis D, Memeo R, Soler L, Marescaux J, Mutter D, Pessaux P. Augmented reality guidance for the resection of missing colorectal liver metastases: an initial experience. World Journal of Surgery 2015; Epub.
15. Al Knawy B, Shiffman M. Percutaneous liver biopsy in clinical practice. Liver International 2007;27:1166-1173.
16. Hennessey H, Valenti D, Cabrera T, Panet-Raymond V, Roberge D. Cardiac embolization of an implanted fiducial marker for hepatic stereotactic body radiotherapy: a case report. Journal of Medical Case Reports 2009;3:140.
17. Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Annals of Surgery 2004;239:818-825.